Ozmosi | Carlumab Drug Profile

Product Description

a human IgG1kappa anti-CCL2 mAb (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24928772/)

Mechanisms of Action: CCL2 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Centocor
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Idiopathic Pulmonary Fibrosis|Idiopathic Interstitial Pneumonias|Prostate Cancer

Phase 1: Hypertension|Oncology Solid Tumor Unspecified

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT00537368	CR013699	P1	Completed	Hypertension	None	2019-03-21	Treatments
NCT01204996	CR016462	P1	Completed	Oncology Solid Tumor Unspecified	None	2024-11-27	Primary Endpoints
2008-001281-86	2008-001281-86	P2	Completed	Idiopathic Pulmonary Fibrosis	2012-08-14	2022-03-12	Treatments
NCT00786201	CR015235	P2	Completed	Idiopathic Pulmonary Fibrosis\|Idiopathic Interstitial Pneumonias	2012-01-01	2019-03-18
2009-011251-48	2009-011251-48	P2	Completed	Prostate Cancer	2011-07-06	2022-03-13	Treatments
NCT00992186	CR015907	P2	Completed	Prostate Cancer	2011-07-01	2019-03-19	Treatments
2009-011250-17	2009-011250-17	P2	Completed	Unknown	2010-07-14	2022-03-13	Treatments

Recent News Events

Date	Type	Title
06/01/2023	PubMed	Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis.
03/30/2023	PubMed	Bioinformatics-integrated screening of systemic sclerosis-specific expressed markers to identify therapeutic targets.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Carlumab

Alternative Names: carlumab, cnto-888, cnto 888, cnto888 Clinical Status: Inactive Latest Update: 2023-06-01 Latest Update Note: PubMed Publication